[Skip to Content]
[Skip to Content Landing]
Article
November 1990

Indomethacin in the Treatment of Lithium-Induced Nephrogenic Diabetes Insipidus

Author Affiliations

Vienna, Austria

Arch Intern Med. 1990;150(11):2420. doi:10.1001/archinte.1990.00390220146042
Abstract

To the Editor. — In a recent communication, Allen et al1 report that indomethacin, a compound used for some time2 to reduce diuresis in nephrogenic diabetes insipidus, may also be effective in patients in whom this condition has been induced by lithium therapy. Since in the interpretation of their results, indomethacin is used virtually synonymously with "NSAID" the authors should be reminded that both in healthy subjects and in a patient with nephrogenic diabetes insipidus, the comparison of the potential antidiuretic effect of indomethacin vs that of acetylsalicylic acid, another inhibitor of cyclo-oxygenase activity, has indicated that a mechanism other than cyclo-oxygenase inhibition is involved in the effect of indomethacin.3,4 To relate the antidiuretic action of indomethacin in nephrogenic diabetes insipidus only to its effect on cyclo-oxygenase is therefore an oversimplification.

First Page Preview View Large
First page PDF preview
First page PDF preview
×